Skip to main content

CJC-1295 Ipamorelin Therapy

Meaning

CJC-1295 Ipamorelin Therapy is a combined peptide protocol designed to stimulate the pulsatile and physiological release of endogenous Human Growth Hormone (HGH) from the pituitary gland. CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog that sustains the stimulation, while Ipamorelin is a Growth Hormone Releasing Peptide (GHRP) that enhances the pulse amplitude. This therapeutic combination works synergistically to elevate circulating growth hormone and Insulin-like Growth Factor 1 (IGF-1) levels in a manner that closely mimics the body’s natural youthful secretion pattern. The clinical goal is to mitigate the effects of somatopause without the use of synthetic HGH.